- Bloomberg
Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks
(Bloomberg) -- The new class of weight-loss drugs being tested as cure-alls for everything from knee replacements to liver disease keeps throwing corners of the stock market into disarray.Most Read from BloombergNvidia’s 13% Stock Rout Has Traders Scouring Charts for SupportBuzzFeed Struggles to Sell Owner of Hit YouTube Show ‘Hot Ones’Jain Global Raises $5.3 Billion, Secures Cash From Abu DhabiHow Long Can High Rates Last? Bond Markets Say Maybe ForeverTech Hits Stocks as Nvidia Extends Selloff
- Zacks
Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes
Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.
- Insider Monkey
Insulet (PODD) Faces Increasing Competition
ClearBridge Investments, an investment management company, released its “ClearBridge Select Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The positive momentum in 2023 continued in the first quarter of 2024, the stocks surged on the expectation of a soft landing of the economy and a slowdown in rate […]
